Local AEs - Cohort 1a & 1b:

• 72% of participants reported solicited adverse effects
• Solicited local AES were reported in 58% of participants - mostly grade 1/2, most frequent AE was injection site pain
• Three participants Reported grade 3 pain Systemic AEs - Cohort 1a & 1b:
• 64% of participants reported systemic AEs, mostly grade 1/grade 2
• 11% reported grade 3 systemic AES -Most common was fatigue, headache and myalgia
• Fevers occurred in 19% of participants, grade 3 fevers in 5% of participants Local AEs - Cohort 3:
• 27% of participants reported local AEs - mostly grade 1/2
• One participant reported grade 3 swelling and erythema Systemic AEs - Cohort 3:
• 14% of participants reported grade1 or 2 fevers, no grade 3 Overall
• No grade 4 AEs, no participant discontinued do to AE
• two SAEs - one hypotension to vaccine related, one hospitalization of fever vaccine related but recovered within 12 hours